Texas Prostate Completes 100th TULSA Procedure, Revolutionizing Prostate Care

Texas Prostate, under the leadership of Dr. James Cochran, has completed its 100th TULSA Procedure at Dallas Medical Center. The milestone highlights the growing adoption of this MRI-guided therapy for prostate conditions. Profound Medical Corp., the developer of the technology, acknowledged the achievement as a significant step in expanding treatment options. The TULSA Procedure uses robotically controlled ultrasound to heat prostate tissue to a precise 'kill temperature' of 55-57°C. Unlike traditional methods, it preserves surrounding nerves and anatomy, reducing side effects. Real-time MRI thermography allows continuous monitoring and automatic temperature adjustments during treatment.

Dr. Cochran initially offered HIFU (High-Intensity Focused Ultrasound) but switched to TULSA due to its broader applications. The procedure treats both prostate cancer and benign prostatic hyperplasia (BPH) with improved safety. Its precision comes from in-bore MRI visualization, ensuring targeted therapy without incisions.

Since transitioning to a Medicare-based model at Dallas Medical Center, Dr. Cochran's team has seen a 500% increase in TULSA Procedure numbers. The TULSA-PRO platform, Profound Medical's flagship system, has gained traction since its FDA approval in 2021. While exact figures on U.S. clinics offering the procedure remain undisclosed, major medical centres and urology practices nationwide have adopted it. The 100th TULSA Procedure at Texas Prostate marks a key development in prostate disease treatment. The technology's precision and safety profile continue to attract specialists like Dr. Cochran. With growing adoption, the procedure is set to become a standard option for men with prostate cancer or BPH.